Hemodynamic Profiles During Pulmonary Artery Pressure Sensor Implantation: Risk Stratification in Chronic Heart Failure With Reduced Ejection Fraction.
Daniel Jabr, Rachel Pedersen, Amogha Dahal...
https://pubmed.ncbi.nlm.nih.gov/41022266/Actively Recruiting
Led by Abbott Medical Devices · Updated on 2026-06-10
850
Participants Needed
68
Research Sites
156 weeks
Total Duration
This research aims to evaluate the safety and effectiveness of the HeartMate 3 left ventricular assist system LVAS compared to guideline-directed medical therapy GDMT in adults with advanced heart failure HF who are ambulatory and not dependent on intravenous inotropes. The study focuses on patients with elevated mean pulmonary artery pressure PAP due to left ventricular failure, a group at higher risk of worsening HF despite optimal medical treatment. The trial seeks to identify whether earlier intervention with LVAS benefits these patients. Participants will be divided into groups based on their mean PAP levels measured by the CardioMEMS PA Sensor device, which monitors pulmonary artery pressure remotely. Those with elevated mean PAP 30 mmHg are randomized either to receive the HeartMate 3 LVAS within 14 days or to continue with GDMT per heart failure guidelines. Patients with lower mean PAP <30 mmHg join a single-arm registry to observe their disease progression while on medical therapy. All participants either have or will receive the CardioMEMS PA Sensor implant as part of the study. During the trial, participants will undergo regular assessments including survival without major complications such as disabling stroke or worsening heart failure requiring urgent interventions over two years. Quality of life, exercise capacity via six-minute walk tests, hospitalization rates, and adverse events will also be closely monitored. The study involves approximately 850 subjects across about 75 sites worldwide and aims to provide data on how best to manage advanced HF patients using mechanical circulatory support versus medical therapy alone.
CONDITIONS
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
N
Nourdine Chakouri, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Abbott Medical Devices
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | HeartMate 3 LVAS with CardioMEMS | CardioMEMS-Guided Medical Therapy |
|---|---|---|
| What is it? | Implantation of the HeartMate 3 Left Ventricular Assist System, a fully magnetically levitated mechanical pump, alongside CardioMEMS pulmonary artery (PA) sensor for ongoing heart failure monitoring and management. | Continued optimal guideline-directed medical therapy for heart failure, guided by regular pulmonary artery pressure monitoring using the CardioMEMS PA sensor. |
| Role in the trial | Investigational therapy: tests whether adding LVAS to CardioMEMS-guided management improves survival and reduces heart failure progression in high-risk patients. | Comparator: assesses outcomes in patients managed with optimal guideline-directed medication using CardioMEMS for detailed hemodynamic monitoring. |
| Primary use | Relief of symptoms and prevention of heart failure progression by providing long-term circulatory support, potentially serving as a bridge to transplant or destination therapy in advanced disease, monitored for optimization by CardioMEMS. | Maintaining optimal symptom control and delaying disease progression in advanced heart failure using all recommended heart failure medications with close adjustment using CardioMEMS hemodynamic readings. |
| How it is given or performed | Surgical implantation of the HeartMate 3 mechanical pump in the left ventricle, with patients also managed remotely via CardioMEMS pulmonary artery pressure sensor. | Continued administration of oral and/or parenteral guideline-directed heart failure medications. CardioMEMS sensor provides ongoing pulmonary artery pressure readings to inform therapy adjustments. |
| Evidence status | Efficacy and safety for the combination of HeartMate 3 LVAS and CardioMEMS-guided care in this patient group are currently under investigation; published outcome data for this specific combined approach are not yet established. | CardioMEMS-guided management is supported by published evidence as a tool for risk stratification and outpatient optimization in chronic heart failure with reduced ejection fraction. Guideline-directed medications remain the cornerstone of treatment. |
| Important limitations | The HeartMate 3 LVAS requires surgical implantation and ongoing device management. Study outcomes for the combined approach are still being gathered, and it is not clear if this combined therapy will be superior to optimized medical management alone in this population. | Despite established role in symptom management, many patients with advanced heart failure may still progress or require device-based support; real-world effectiveness depends on patient adherence and eligibility for all medications. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 2 years
Participants with elevated pulmonary artery pressure will be randomly assigned to receive the HeartMate 3 device within 14 days or continue guideline-directed medical therapy. Participants with lower pressure will continue medical therapy in a single arm registry.
Regular visits as part of monitoring and assessments
Duration - 2 years
Participants will be monitored for survival, quality of life, exercise capacity, hospitalizations, and adverse events over two years.
Periodic assessments throughout follow-up
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Daniel Jabr, Rachel Pedersen, Amogha Dahal...
https://pubmed.ncbi.nlm.nih.gov/41022266/Abbott Medical Devices
Lead Sponsor